BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parashar D, Rajendran V, Shukla R, Sistla R. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. European Journal of Pharmaceutical Sciences 2020;142:105159. [DOI: 10.1016/j.ejps.2019.105159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Lin X, Lin L, Wu J, Jiang W, Wu J, Yang J, Chen C. A targeted siRNA-loaded PDL1-exosome and functional evaluation against lung cancer. Thorac Cancer 2022. [PMID: 35545838 DOI: 10.1111/1759-7714.14445] [Reference Citation Analysis]
2 Bukhari SNA. Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials. Pharmaceutics 2022;14:866. [PMID: 35456698 DOI: 10.3390/pharmaceutics14040866] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ma Z, Zheng Y, Chao Z, Chen H, Zhang Y, Yin M, Shen J, Yan S. Visualization of the process of a nanocarrier-mediated gene delivery: stabilization, endocytosis and endosomal escape of genes for intracellular spreading. J Nanobiotechnology 2022;20:124. [PMID: 35264206 DOI: 10.1186/s12951-022-01336-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
4 Mehanna MM, Abla KK. siRNA nanohybrid systems: false hope or feasible answer in cancer management. Ther Deliv 2022. [PMID: 35105155 DOI: 10.4155/tde-2021-0068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bidar N, Darroudi M, Ebrahimzadeh A, Safdari M, de la Guardia M, Baradaran B, Goodarzi V, Oroojalian F, Mokhtarzadeh A. Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances. Eur J Pharmacol 2022;915:174639. [PMID: 34919890 DOI: 10.1016/j.ejphar.2021.174639] [Reference Citation Analysis]
6 Akhilesh, Uniyal A, Gadepalli A, Tiwari V, Allani M, Chouhan D, Ummadisetty O, Verma N, Tiwari V. Unlocking the potential of TRPV1 based siRNA therapeutics for the treatment of chemotherapy-induced neuropathic pain. Life Sci 2022;288:120187. [PMID: 34856209 DOI: 10.1016/j.lfs.2021.120187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Roy P, Saha S, Chakraborty J. Looking into the possibilities of cure of the type 2 diabetes mellitus by nanoparticle-based RNAi and CRISPR-Cas9 system: A review. Journal of Drug Delivery Science and Technology 2021;66:102830. [DOI: 10.1016/j.jddst.2021.102830] [Reference Citation Analysis]
8 Sun MJ, Teng Z, Fan PS, Chen XG, Liu Y. Bridging micro/nano-platform and airway allergy intervention. J Control Release 2021;341:364-82. [PMID: 34856226 DOI: 10.1016/j.jconrel.2021.11.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zhou L, Rubin LE, Liu C, Chen Y. Short interfering RNA (siRNA)-Based Therapeutics for Cartilage Diseases. Regen Eng Transl Med 2020;7:283-90. [PMID: 34589570 DOI: 10.1007/s40883-020-00149-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Du J, Shao Y, Hu Y, Chen Y, Cang J, Chen X, Pei W, Miao F, Shen Y, Muddassir M, Zhang Y, Zhang J, Teng G. Multifunctional Liposomes Enable Active Targeting and Twinfilin 1 Silencing to Reverse Paclitaxel Resistance in Brain Metastatic Breast Cancer. ACS Appl Mater Interfaces 2021;13:23396-409. [PMID: 33982563 DOI: 10.1021/acsami.1c02822] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
11 Mendonça MCP, Kont A, Aburto MR, Cryan JF, O'Driscoll CM. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System. Mol Pharm 2021;18:1491-506. [PMID: 33734715 DOI: 10.1021/acs.molpharmaceut.0c01238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
12 Belete TM. The Current Status of Gene Therapy for the Treatment of Cancer. Biologics 2021;15:67-77. [PMID: 33776419 DOI: 10.2147/BTT.S302095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
13 Oner E, Kotmakci M, Baird AM, Gray SG, Debelec Butuner B, Bozkurt E, Kantarci AG, Finn SP. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. J Nanobiotechnology 2021;19:71. [PMID: 33685469 DOI: 10.1186/s12951-021-00781-z] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
14 Panda K, Alagarasu K, Parashar D. Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication. Molecules 2021;26:956. [PMID: 33670247 DOI: 10.3390/molecules26040956] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Dutta K, Das R, Medeiros J, Thayumanavan S. Disulfide Bridging Strategies in Viral and Nonviral Platforms for Nucleic Acid Delivery. Biochemistry 2021;60:966-90. [PMID: 33428850 DOI: 10.1021/acs.biochem.0c00860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ding L, Tang S, Wyatt TA, Knoell DL, Oupický D. Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges. J Control Release 2021;330:977-91. [PMID: 33181203 DOI: 10.1016/j.jconrel.2020.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
17 Francis JE, Skakic I, Dekiwadia C, Shukla R, Taki AC, Walduck A, Smooker PM. Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery. Vaccines (Basel) 2020;8:E551. [PMID: 32967285 DOI: 10.3390/vaccines8030551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 Suzuki T, Suzuki Y, Hihara T, Kubara K, Kondo K, Hyodo K, Yamazaki K, Ishida T, Ishihara H. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production. Int J Pharm 2020;588:119792. [PMID: 32827675 DOI: 10.1016/j.ijpharm.2020.119792] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
19 Liu C, Zhang L, Zhu W, Guo R, Sun H, Chen X, Deng N. Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy. Mol Ther Methods Clin Dev 2020;18:751-64. [PMID: 32913882 DOI: 10.1016/j.omtm.2020.07.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
20 He Y, Zhan C, Pi C, Zuo Y, Yang S, Hu M, Bai Y, Zhao L, Wei Y. Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique. AAPS PharmSciTech 2020;21:170. [PMID: 32529303 DOI: 10.1208/s12249-020-01711-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]